A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

NCT04559971 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: SLN124
DRUG: Placebo

Sponsor

Silence Therapeutics plc